Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood.

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder and a significant cause of dementia in elderly individuals, with a growing prevalence in our aging population. Extracellular amyloid-β peptides (Aβ), intracellular tau proteins, and their phosphorylated forms have gained prominence as critical biomarkers for early and precise diagnosis of AD, correlating with disease progression and response to therapy. The high costs and invasiveness of conventional diagnostic methods, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), limit their suitability for large-scale or routine screening. However, electrochemical (EC) analysis methods have made significant progress in disease detection due to their high sensitivity, excellent specificity, portability, and cost-effectiveness. This article reviews the progress in EC biosensing technologies, focusing on the detection of tau protein biomarkers in the blood (a low-invasive, accessible diagnostic medium). The article then discusses various EC sensing platforms, including their fabrication processes, limit of detection (LOD), sensitivity, and clinical potential to show the role of these sensors as transformers changing the face of AD diagnostics.